The LiBBY trial found that a twice-daily THC plus CBD oil reduced agitation in late-stage dementia. LiBBY means Life's End Benefits of cannaBidiol and tetrahYdrocannabinol, and results were presented July 14, 2026 at AAIC London. The study enrolled 120 hospice-eligible people with late-stage Alzheimer's or other dementia with agitation. It was multicenter, randomized, double-blind, and placebo-controlled, according to the Alzheimer's Association announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What treatment did LiBBY test?
- How much did agitation improve?
- Who took part in the study?
- What should spouses and partners ask now?
What treatment did LiBBY test?
Participants received a novel oral oil with 2 mg THC plus 100 mg CBD twice daily versus placebo for 12 weeks. One report notes titration from a lower week-1 starting dose. The formula was an experimental study-only oil, not a store or dispensary product.
It cannot be replaced with commercial cannabis. Routine physician care continued during the trial. Study visits took place at home, which reduced travel for families.
How much did agitation improve?
Treatment met its primary endpoint at week 2. Cohen-Mansfield Agitation Inventory scores fell 10.61 points with THC and CBD versus 4.35 with placebo, according to MIMS Hong Kong reporting Dr. Jacobo Mintzer.
That 6.27-point gap was statistically strong and lasted through week 12. By week 12, the gap reached 8.23 points. Clinician-rated overall improvement reached 87.2% with THC and CBD versus 23.6% with placebo at week 12. That result was described as nearly 9 in 10 treated participants improving, according to Urban Health Today's trial report.
Who took part in the study?
Participants averaged about age 80, and 55% were women. The trial focused on an end-of-life group that research often overlooks. About 58% came from underrepresented ethnoracial groups.
About 75% lived in community settings rather than facilities. Home visits made participation possible while hospice needs continued. For spouses and partners, this shows home-based hospice research is feasible.
What should spouses and partners ask now?
Non-drug strategies remain first-line for agitation. Any medication change requires shared decision-making with hospice and prescribing clinicians. The practical signal is possible relief within two weeks.
Larger Phase 3 confirmation and regulatory review are still needed, according to the Georgetown University summary. Overall adverse-event rates were similar between groups, though serious events occurred more often in the treatment arm and investigators judged them unrelated to study medication. Bring a full medication list and advance directives to that visit.
- Ask the hospice nurse what agitation triggers they see at home
- Ask the prescriber about current sedating drugs and fall risk
- Ask what comfort measures to try before any new prescription
- Ask how improvement will be tracked week by week
You Might Also Like
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: A Source-Checked Research Briefing for Spouses and Partners
- Repetitive Heading and Brain Health Findings at AAIC 2026: What Researchers Still Need to Learn for Spouses and Partners
- Dementia With Multiple Etiologies in the 2026 NIA Report: Why the Findings May Not Change Care Yet for Spouses and Partners





